Highlights from the 2020 CHDI HD Therapeutics Conference are now here! This year’s Postcard covers HTT-lowering therapeutics, including an
Novartis VIBRANT-HD Update
Update From Novartis Regarding VIBRANT-HD Clinical Trials – December 8, 2022
Dear Huntington disease (HD) community,
We have received a disappointing update on the branaplam/LMI070 Phase 2b study in the VIBRANT-HD trial. After reviewing the data, Novartis has announced that the trial has been discontinued and they are ending development of branaplam in Huntington disease. This difficult and disappointing decision follows an earlier suspension of dosing in the study in August 2022, after findings that it may have been harmful to the nervous system in some participants. The studies were ultimately stopped as many participants receiving branaplam in the study showed signs or symptoms of peripheral neuropathy. For more information on what neuropathy is, and how it affects the body, please see the Novartis info below.
Although this is not the news we were hoping to hear, I want to reiterate our heartfelt thanks to all of our Huntington Heroes who participate in clinical trials to make possible the learning and discovery process. We hope that information from this trial will help inform the development of other therapies.
We encourage you to read through the information provided by Novartis.
HD Clinics: Questions specific to trial participation can be discussed with the HD clinic you attend. For information on the HD clinic near you: https://www.huntingtonsociety.ca/hd-clinics-in-canada/
HSC Family Services (FS) are available to provide support, education on HD, resources and referrals. Individuals and families can find the contact information for the nearest FS team member here: https://www.huntingtonsociety.ca/family-services-team-list/
Huntington Society of Canada